Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Lancet Oncol. 2013 Jul 25;14(10):999–1008. doi: 10.1016/S1470-2045(13)70309-7

Figure 2. Trial profile.

Figure 2

*372 patients (192 non-purged, 180 purged) received a transplant, including those who received the PBSC product to which they were allocated (randomised) and those who were crossovers. †One additional patient who received a transplant was retrospectively (post-transplant) determined by the treating institution to have had progressive disease at the end of induction; thus table 1 presents a total of 38 patients in the purged group with end of induction progressive disease. ‡Patients alive at last contact were censored in survival analysis.